Analysts Set The Cooper Companies, Inc. (NASDAQ:COO) Target Price at $115.00

Shares of The Cooper Companies, Inc. (NASDAQ:COO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the thirteen analysts that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $115.00.

Several brokerages recently commented on COO. Robert W. Baird upped their price target on shares of Cooper Companies from $118.00 to $125.00 and gave the company an "outperform" rating in a report on Thursday, August 29th. Wells Fargo & Company boosted their price objective on shares of Cooper Companies from $110.00 to $115.00 and gave the stock an "overweight" rating in a research note on Thursday, August 29th. Jefferies Financial Group upgraded shares of Cooper Companies from a "hold" rating to a "buy" rating and upped their price target for the company from $107.00 to $115.00 in a research note on Tuesday, July 16th. Stifel Nicolaus restated a "buy" rating and set a $115.00 price target (up previously from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Finally, Piper Sandler increased their price objective on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an "overweight" rating in a research note on Thursday, August 29th.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, CAO Agostino Ricupati sold 1,601 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total value of $172,956.03. Following the transaction, the chief accounting officer now directly owns 4,818 shares of the company's stock, valued at approximately $520,488.54. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CAO Agostino Ricupati sold 1,601 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total value of $172,956.03. Following the completion of the transaction, the chief accounting officer now owns 4,818 shares in the company, valued at $520,488.54. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Daniel G. Mcbride sold 114,992 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the transaction, the chief operating officer now owns 44,696 shares of the company's stock, valued at $4,714,534.08. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 256,373 shares of company stock valued at $27,637,427. 2.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cooper Companies

A number of large investors have recently added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Cooper Companies by 248.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company's stock worth $25,000 after purchasing an additional 174 shares during the last quarter. Covestor Ltd raised its holdings in Cooper Companies by 305.9% in the first quarter. Covestor Ltd now owns 276 shares of the medical device company's stock valued at $28,000 after buying an additional 208 shares during the period. Innealta Capital LLC purchased a new position in Cooper Companies in the second quarter valued at approximately $25,000. Crewe Advisors LLC raised its holdings in Cooper Companies by 286.4% in the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company's stock valued at $30,000 after buying an additional 252 shares during the period. Finally, Clearstead Trust LLC purchased a new position in Cooper Companies in the first quarter valued at approximately $36,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies Stock Up 0.5 %

COO traded up $0.52 on Friday, hitting $107.82. The company had a trading volume of 3,270,373 shares, compared to its average volume of 981,651. Cooper Companies has a 52-week low of $75.93 and a 52-week high of $112.38. The stock has a fifty day simple moving average of $105.73 and a 200-day simple moving average of $96.71. The firm has a market capitalization of $21.47 billion, a P/E ratio of 60.07, a P/E/G ratio of 2.53 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.99 and a quick ratio of 1.18.

Cooper Companies (NASDAQ:COO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $997.30 million. During the same quarter last year, the firm earned $0.84 earnings per share. The firm's quarterly revenue was up 7.8% compared to the same quarter last year. As a group, equities analysts expect that Cooper Companies will post 3.65 EPS for the current fiscal year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.